Clinical Trial Update: Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating acalabrutinib alone and with pembrolizumab in ovarian cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Acerta Pharma BV | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-09-12